Piramal Pharma Limited Announces Results for Q1FY26
MUMBAI, India, July 28, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, and health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2025.
Consolidated Financial Highlights
(in ₹ Crores or as stated)
Particulars
Q1FY26
Q1FY25
YoY Growth
Revenue from Operations
1,934
1,951
(1) %
CDMO
997
1,057
(6) %
CHG
637
631
1 %
PCH
302
263
15 %
EBITDA
165
224
(26) %
EBITDA Margin
9 %
11 %
PAT (after exceptional item)
(82)
(89)
8 %
Key Highlights for Q1FY26
Revenue from Operations stood at ₹ 1,934 crores vs ₹ 1,951 crores in Q1FY25. Excluding the impact of destocking in one of the large CDMO product, the YoY revenue growth was in early double-digit
EBITDA margin at 9% vs 11% in Q1FY25. Impact of inventory destocking, partly offset by improved profitability of the overseas facilities in the CDMO business
Net-Debt to EBITDA ratio at 2.6x
Best-in-Class Quality Track Record – Successfully closed USFDA inspection at Aurora facility (Canada) with zero observations. Continue to maintain our 'Zero OAIs' status since 2011
Sustainability Efforts Yielding Results, Assigned an ESG rating of '61' for FY2024 by NSE Sustainability Ratings and Analytics Limited
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and e-commerce sales.
Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE."
Key Business Highlights for Q1 FY2026
Contract Development and Manufacturing Organization (CDMO):
- Mid-teens growth in base business i.e. excluding ...